ProKidney Corp. (NASDAQ:PROK - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $7.13 and last traded at $5.94, with a volume of 120847536 shares traded. The stock had previously closed at $3.73.
Analyst Ratings Changes
Several research analysts recently commented on PROK shares. Bank of America cut ProKidney from a "neutral" rating to an "underperform" rating and reduced their price target for the company from $3.00 to $1.00 in a research report on Monday, June 30th. Wall Street Zen raised ProKidney from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Citigroup raised their price objective on ProKidney from $6.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $5.33.
Check Out Our Latest Research Report on PROK
ProKidney Trading Up 19.4%
The company has a 50 day moving average price of $0.89 and a 200-day moving average price of $1.14. The company has a market cap of $1.52 billion, a P/E ratio of -8.63 and a beta of 1.26.
ProKidney (NASDAQ:PROK - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. The firm had revenue of $0.23 million for the quarter. Equities analysts expect that ProKidney Corp. will post -0.57 earnings per share for the current year.
Insider Transactions at ProKidney
In related news, insider Control Empresarial De Capital acquired 387,393 shares of the firm's stock in a transaction on Tuesday, April 22nd. The stock was purchased at an average cost of $0.71 per share, with a total value of $275,049.03. Following the acquisition, the insider owned 73,842,723 shares of the company's stock, valued at approximately $52,428,333.33. This trade represents a 0.53% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Darin J. Weber sold 103,480 shares of the business's stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $3.02, for a total value of $312,509.60. The disclosure for this sale can be found here. Insiders purchased a total of 755,498 shares of company stock valued at $545,766 over the last ninety days. 41.49% of the stock is currently owned by corporate insiders.
Institutional Trading of ProKidney
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC grew its holdings in shares of ProKidney by 106.4% in the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company's stock valued at $46,000 after acquiring an additional 27,098 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of ProKidney by 57.3% in the fourth quarter. ProShare Advisors LLC now owns 30,879 shares of the company's stock valued at $52,000 after acquiring an additional 11,250 shares in the last quarter. Sei Investments Co. bought a new position in shares of ProKidney in the fourth quarter valued at approximately $69,000. Deutsche Bank AG grew its holdings in shares of ProKidney by 49.4% in the first quarter. Deutsche Bank AG now owns 86,337 shares of the company's stock valued at $76,000 after acquiring an additional 28,546 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of ProKidney in the fourth quarter valued at approximately $88,000. 51.59% of the stock is owned by institutional investors.
About ProKidney
(
Get Free Report)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
See Also
Before you consider ProKidney, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.
While ProKidney currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
